These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 16919261

  • 1. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
    Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):11-8. PubMed ID: 16919261
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
    Matsui T, Yamagishi S, Nakamura K, Inoue H.
    J Int Med Res; 2006 Sep 28; 34(6):671-5. PubMed ID: 17295000
    [Abstract] [Full Text] [Related]

  • 5. Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
    Matsui T, Yamagishi S, Nakamura K, Inoue H.
    J Int Med Res; 2007 Sep 28; 35(6):886-91. PubMed ID: 18084847
    [Abstract] [Full Text] [Related]

  • 6. The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha.
    Shimozawa M, Naito Y, Manabe H, Uchiyama K, Katada K, Kuroda M, Nakabe N, Yoshida N, Yoshikawa T.
    Redox Rep; 2004 Sep 28; 9(6):354-9. PubMed ID: 15720832
    [Abstract] [Full Text] [Related]

  • 7. Isorhamnetin prevent endothelial cell injuries from oxidized LDL via activation of p38MAPK.
    Bao M, Lou Y.
    Eur J Pharmacol; 2006 Oct 10; 547(1-3):22-30. PubMed ID: 16963021
    [Abstract] [Full Text] [Related]

  • 8. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.
    Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T.
    J Cardiovasc Pharmacol; 2004 May 10; 43(5):724-30. PubMed ID: 15071361
    [Abstract] [Full Text] [Related]

  • 9. SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.
    Takahashi K, Shimokado K, Yoshida M.
    Eur J Pharmacol; 2006 Dec 15; 552(1-3):162-9. PubMed ID: 17067573
    [Abstract] [Full Text] [Related]

  • 10. Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits.
    Chen YH, Lin SJ, Chen JW, Ku HH, Chen YL.
    Br J Pharmacol; 2002 Jan 15; 135(1):37-47. PubMed ID: 11786478
    [Abstract] [Full Text] [Related]

  • 11. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
    Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H.
    Drugs Exp Clin Res; 2005 Jan 15; 31(5-6):215-9. PubMed ID: 16425978
    [Abstract] [Full Text] [Related]

  • 12. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
    Ohyama T, Sato K, Kishimoto K, Yamazaki Y, Horiguchi N, Ichikawa T, Kakizaki S, Takagi H, Izumi T, Mori M.
    Br J Pharmacol; 2012 Feb 15; 165(4b):1173-87. PubMed ID: 21790536
    [Abstract] [Full Text] [Related]

  • 13. Anti-Inflammatory effect of Buddleja officinalis on vascular inflammation in human umbilical vein endothelial cells.
    Lee YJ, Moon MK, Hwang SM, Yoon JJ, Lee SM, Seo KS, Kim JS, Kang DG, Lee HS.
    Am J Chin Med; 2010 Feb 15; 38(3):585-98. PubMed ID: 20503474
    [Abstract] [Full Text] [Related]

  • 14. Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-α-treated endothelial cells via NADPH oxidase-dependent IκB kinase/NF-κB pathway.
    Yan S, Zhang X, Zheng H, Hu D, Zhang Y, Guan Q, Liu L, Ding Q, Li Y.
    Free Radic Biol Med; 2015 Jan 15; 78():190-201. PubMed ID: 25463279
    [Abstract] [Full Text] [Related]

  • 15. Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells.
    Matsubara M, Hasegawa K.
    Eur J Pharmacol; 2004 Sep 13; 498(1-3):303-14. PubMed ID: 15364009
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K, Yamagishi S, Inoue H.
    Med Hypotheses; 2005 Sep 13; 65(1):155-7. PubMed ID: 15893134
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
    Kurobe H, Matsuoka Y, Hirata Y, Sugasawa N, Maxfield MW, Sata M, Kitagawa T.
    J Thorac Cardiovasc Surg; 2013 Dec 13; 146(6):1501-8. PubMed ID: 23535154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.